Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma.

ABSTRACT: The blockade of immunological checkpoints has been successfully employed for the treatment of various solid neoplasms including melanoma, mesothelioma, non-small cell lung carcinoma, and renal cell carcinoma. A recent study indicates that the vast majority of patients with advanced, heavily pretreated Hodgkin's lymphoma (HL) also respond to a monoclonal antibody targeting programmed cell death 1 (PDCD1, best known as PD-1). Thus, checkpoint blockers may soon become part of our therapeutic armamentarium against hematological tumors. This would be particularly important as it would spare (at least some) patients the deleterious toxic effects of combinatorial chemotherapies and bone marrow transplantation. We anticipate that the realm of immunotherapy will eventually conquer vast portions of

SUBMITTER: Kroemer G 

PROVIDER: S-EPMC4485757 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature